University of Texas: Study Demonstrates Liquid Biopsy as Effective Predictor of Stage III Melanoma Relapse and Treatment
February 06, 2020
February 06, 2020
HOUSTON, Texas, Feb. 6 [TNSmedicalresearch] -- The University of Texas's MD Anderson Cancer Center issued the following news release:
* * *
- Assessment of circulating tumor cells at first clinic visit predicted relapse within six months; may help identify patients likely to benefit from rigorous imaging surveillance and additional therapy
* * *
A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CT . . .
* * *
- Assessment of circulating tumor cells at first clinic visit predicted relapse within six months; may help identify patients likely to benefit from rigorous imaging surveillance and additional therapy
* * *
A study at The University of Texas MD Anderson Cancer Center showed that circulating tumor cells (CT . . .